Abstract
Psoriasis is a chronic inflammatory skin disease with a significant number of patients suffering from additional joint involvement and other co-morbidities. The precise pathomechanisms of this disease are still unknown. But based on recent findings a picture emerges putting a new subset of inflammatory T cells, so-called Th17 T cells, into the centre of psoriasis pathogenesis. These cells secrete interleukin (IL)-17 and a further set of so-called Th17 cytokines such as IL-21 and IL-22, the latter of which appears to significantly contribute to the epidermal changes observed in this disease. Differentiation and maintenance of Th17 cells depends on IL-23 and transforming growth factor (TGF)-β, secreted by activated monocytes or macrophages within the dermal compartment. In recent years, a plethora of new treatment approaches was introduced using antibodies or small molecule inhibitors specifically targeting inflammatory cytokines, cellular receptors or signalling mechanisms. Based on current results from large clinical trials, a more individualized treatment for affected patients may be achieved in the near future. In this review, we summarize the current knowledge about treatment of psoriasis with biological agents targeting inflammatory mechanisms.
Keywords: Autoimmunity, chronic inflammation, antibodies, Th17 cells, clinical trials
Current Drug Discovery Technologies
Title: Current Treatment of Psoriasis with Biologics
Volume: 6 Issue: 4
Author(s): Manfred Kunz
Affiliation:
Keywords: Autoimmunity, chronic inflammation, antibodies, Th17 cells, clinical trials
Abstract: Psoriasis is a chronic inflammatory skin disease with a significant number of patients suffering from additional joint involvement and other co-morbidities. The precise pathomechanisms of this disease are still unknown. But based on recent findings a picture emerges putting a new subset of inflammatory T cells, so-called Th17 T cells, into the centre of psoriasis pathogenesis. These cells secrete interleukin (IL)-17 and a further set of so-called Th17 cytokines such as IL-21 and IL-22, the latter of which appears to significantly contribute to the epidermal changes observed in this disease. Differentiation and maintenance of Th17 cells depends on IL-23 and transforming growth factor (TGF)-β, secreted by activated monocytes or macrophages within the dermal compartment. In recent years, a plethora of new treatment approaches was introduced using antibodies or small molecule inhibitors specifically targeting inflammatory cytokines, cellular receptors or signalling mechanisms. Based on current results from large clinical trials, a more individualized treatment for affected patients may be achieved in the near future. In this review, we summarize the current knowledge about treatment of psoriasis with biological agents targeting inflammatory mechanisms.
Export Options
About this article
Cite this article as:
Kunz Manfred, Current Treatment of Psoriasis with Biologics, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869092
DOI https://dx.doi.org/10.2174/157016309789869092 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Hot Topic: Cardiovascular Disease Biomarkers: from Tradition to Modernity)
Current Topics in Medicinal Chemistry Novel Therapeutic Agents in the Management of Hemorrhage and Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Assessment of Endothelial Function by Positron Emission Tomography
Current Cardiology Reviews Sleep Apnea: an Underestimated Cause of Resistant Hypertension
Current Hypertension Reviews Targeting Water in the Brain: Role of Aquaporin-4 in Ischemic Brain Edema
Current Drug Targets Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery The Glycogen Synthase Kinase-3 in the Regulation of Ion Channels and Cellular Carriers
Current Medicinal Chemistry Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science Circulating ACE2 in Cardiovascular and Kidney Diseases
Current Medicinal Chemistry Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews Anti-Biofilm Strategies and the Need for Innovations in Wound Care
Recent Patents on Anti-Infective Drug Discovery Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design Statins in Bacteremia, Sepsis and Pneumonia: Have We Found the Holy Grail?
Recent Patents on Inflammation & Allergy Drug Discovery Early Vascular Ageing (EVA): Definitions and Clinical Applicability
Current Hypertension Reviews Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Current Pharmaceutical Design Recent Advances in Metabolomics
Current Metabolomics Potential Application of Dietary Polyphenols from Red Wine to Attaining Healthy Ageing
Current Topics in Medicinal Chemistry Recent Advances in Bioreactors in Tissue Engineering and Regenerative Medicine
Current Tissue Engineering (Discontinued)